Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Exclusion Criteria

• •History of prior treatment with immune checkpoint antibodies (e.g. anti-PD1, anti-PDL1, anti-CTLA4 antibody) or co-stimulatory agonist antibodies (e.g. anti-41BB, anti-OX40)
• •\* Prior intravesical treatment with Bacillus Calmette-Guerin (BCG) is allowed; however, the last dose must be at least 6 weeks from time of enrollment and patients must have documented progressive disease at least 6 weeks from completion of last BCG
• •Diagnosis of immunodeficiency including history of human immunodeficiency virus (HIV)
• •Receiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to first injection of \[18F\]F-AraG
• •\* Topical and inhaled corticosteroids are allowed
• •Prior allogeneic stem cell or solid organ transplant
• •Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
• •Biopsy or resection of the primary tumor within 14 days the first injection of \[18F\]F-AraG
• •Contraindication to magnetic resonance (MRI) imaging, as determined through review of the University of California, San Francisco (UCSF) MRI screening form by study investigator
• •Evidence of active infection within 14 days of study enrollment
• •Female patients who are pregnant or breastfeeding
• •Inability to receive furosemide (Lasix) in the opinion of the treating investigator
• •Patients that plan to receive off-label use of anti-PD1 or anti-PDL1